137945-53-0 Usage
Description
[(6AR,10AR)-1-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-3-(1,1-DIMETHYL-HEPTYL)-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9-YL]-METHANOL, also known as a synthetic cannabinoid, is a derivative of the natural compound THC. It is characterized by the presence of a silanyloxy group and a tertiary butyl group, which contribute to its stability and enhanced pharmacological properties. [(6AR,10AR)-1-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-3-(1,1-DIMETHYL-HEPTYL)-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9-YL]-METHANOL acts as a potent agonist at the cannabinoid receptors in the brain and peripheral tissues, producing effects similar to those of THC. It has garnered interest for its potential therapeutic applications, particularly in the treatment of pain, inflammation, and neurodegenerative disorders. However, its use is also associated with various health risks and regulatory concerns due to its psychoactive properties and potential for abuse.
Uses
Used in Pharmaceutical Applications:
[(6AR,10AR)-1-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-3-(1,1-DIMETHYL-HEPTYL)-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9-YL]-METHANOL is used as a therapeutic agent for the treatment of pain, inflammation, and neurodegenerative disorders. Its agonistic action at cannabinoid receptors makes it a potential candidate for managing these conditions.
Used in Research and Development:
In the field of scientific research, [(6AR,10AR)-1-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-3-(1,1-DIMETHYL-HEPTYL)-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9-YL]-METHANOL is used as a research tool to study the effects and mechanisms of action of cannabinoids on the human body. This helps in understanding the potential therapeutic applications and risks associated with its use.
Used in Regulatory and Safety Assessments:
Due to its psychoactive properties and potential for abuse, [(6AR,10AR)-1-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-3-(1,1-DIMETHYL-HEPTYL)-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9-YL]-METHANOL is also used in regulatory and safety assessments to determine the appropriate guidelines and restrictions for its use in various applications.
Used in Drug Delivery Systems:
Similar to gallotannin, [(6AR,10AR)-1-(TERT-BUTYL-DIMETHYL-SILANYLOXY)-3-(1,1-DIMETHYL-HEPTYL)-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9-YL]-METHANOL may benefit from novel drug delivery systems to enhance its applications and efficacy. Various organic and metallic nanoparticles could be employed as carriers for this synthetic cannabinoid, aiming to improve its delivery, bioavailability, and therapeutic outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 137945-53-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,9,4 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 137945-53:
(8*1)+(7*3)+(6*7)+(5*9)+(4*4)+(3*5)+(2*5)+(1*3)=160
160 % 10 = 0
So 137945-53-0 is a valid CAS Registry Number.
137945-53-0Relevant articles and documents
ANTI-EMETIC USES OF (3R, 4R)-DELTA8-TETRAHYDROCANNABINOL-11-OIC ACIDS
-
Page/Page column title page; 5; 6; figure 1, (2008/06/13)
The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, (3R,4R)-Δ8-THC-11-oic acids, for treating or preventing nausea and relieving symptoms thereof.
Synthetic Nonpsychotropic Cannabinoids with Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities
Burstein, Sumner H.,Audette, Charlene A.,Breuer, Aviva,Devane, William A.,Colodner, Sharona,et al.
, p. 3135 - 3141 (2007/10/02)
Two strategies for the design of therapeutically useful cannabinoids have been combined to produce compounds with greatly increased antiinflammatory activity and with a low potential for adverse side effects.Enantiomeric cannabinoids with a carboxylic acid group at position 7 and with an elongated and branched alkyl sidechain at position 5' have been synthesized and tested for antiinflammatory activity.They were effective when given orally at doses of 10 μg/kg in reducing paw edema in mice that had been induced by either arachidonic acid or platelet activating factor.Leukocyte adhesion to culture dishes was also reduced in peritoneal cells from mice in which the cannabinoids were orally administered in the same dose range as for the paw edema tests.Antinociception could be observed in the mouse hot plate assay; however, little stereochemical preference was seen in contrast to the above tests where the 3R,4R compounds are more active than the 3S,4S enantiomers.Finally, in agreement with earlier reports on the naturally occurring pentyl side chain acids, the synthetic acids showed little activity in producing catalepsy in the mouse, suggesting that they would be nonpsychotropic in humans.